Status:
RECRUITING
EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors
Lead Sponsor:
University Hospital, Clermont-Ferrand
Collaborating Sponsors:
Institut Paoli-Calmettes
CHRU Lille, hematology department
Conditions:
Chronic Myeloid Leukemia (CML)
Chronic Phase
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Primary objective : To identify epigenetic dysregulations of in vivo TKI-resisting CML cells Hypothesis : An epigenetic dysregulation is involved in the in vivo survival of a CML cell subclone despite...
Detailed Description
Chronic myeloid leukemia (CML) is a model of leukemogenesis because the malignant transformation of a hematopoietic stem cell is considered as the consequence of a unique major event: the translocatio...
Eligibility Criteria
Inclusion
- Patient newly diagnosed for Chronic Myeloid Leukemia in chronic phase
- Patient older than 18 years old
- Patient who received no treatment for CML at the time of sampling on D0
- Intention of prescription with first-line treatment with TKI only
- Choice of first-line CML treatment by TKI only
- Patient having signed an informed consent
- Patient with a social security system
Exclusion
- Contra-indication to the use of TKI
- Probability of poor compliance during treatment
- Patients already treated for CML
Key Trial Info
Start Date :
February 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2026
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT03481868
Start Date
February 1 2018
End Date
February 1 2026
Last Update
April 9 2024
Active Locations (16)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Annecy-Genevois
Annecy, France
2
Institut Bergonié
Bordeaux, France
3
CHU Caen
Caen, France
4
CHU Clermont-Ferrand
Clermont-Ferrand, France, 63003